Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nadja Höbel"'
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Patent expirations for several biological products have prompted the development of alternative versions, termed ‘biosimilars’, which have comparable quality, safety and efficacy to a licensed biological medicine (also referred to as the ‘refer
Externí odkaz:
https://doaj.org/article/df569bd8fed445299e27b0c575212bbb
Autor:
David Goldsmith, Christian Combe, Andriy Krendyukov, Nadja Höbel, Frank Dellanna, Andreas Seidl
Publikováno v:
Drug Design, Development and Therapy
Erythropoiesis-stimulating agents, such as recombinant human erythropoietin, are commonly used for the treatment of anemia in patients with chronic kidney disease (CKD). In 2007, HX575 (Binocrit®) became the first biosimilar epoetin alfa to be appro
Publikováno v:
Supportive Care in Cancer
Biosimilars are biological medicines that have been shown to be similar to a reference biological medicine that has already been approved for use. Development of biosimilars is based on a “totality of evidence” approach that involves a series of
Autor:
Juan Pedro López-Siguero, Roland Pfäffle, Philippe Chanson, Mieczyslaw Szalecki, Nadja Höbel, Markus Zabransky
Publikováno v:
Drug Design, Development and Therapy. 11:1489-1495
Publikováno v:
European journal of haematology. 100(3)
Objective Prospective data on the use of granulocyte-colony-stimulating factor (G-CSF) in non-Hodgkin's lymphoma and its aggressive subtypes, including diffuse large B-cell lymphoma (DLBCL), are limited. MONITOR-GCSF is a pan-European, multicenter, p
Publikováno v:
European journal of cancer care. 28(4)
Objective Real-world evidence data on the use of granulocyte colony-stimulating factor (G-CSF) in patients with non-small cell lung cancer (NSCLC) are limited. MONITOR-GCSF is a pan-European, multicentre, prospective, non-interventional study designe
Autor:
Maria Victoria Borrás Pérez, Nadja Höbel, Markus Zabransky, Tomasz Romer, Mieczysław Walczak, Berit Kriström
Publikováno v:
Drug Design, Development and Therapy
Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose homeostasis, and the formation of antibodies to endogenous/exogenous GH. Omnitrope (R) (biosimilar rhGH) was approved by the Europ
Publikováno v:
Annals of Oncology. 28:v560-v561
Publikováno v:
Annals of Oncology. 28:x162
Publikováno v:
Hematological Oncology. 35:351-351